June and July delivered a busy stretch of leadership moves across pharma and biotech. From major R&D appointments at large drugmakers to a wave of CEO, CMO, and commercial hires across emerging ...

There’s a personalisation crisis in today’s marketing. Nearly 99% of marketers believe personalisation helps strengthen ...

Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impinging patient access to new therapies. That is the finding of a survey by Swiss ...

ADC Therapeutics' chief executive, Ameet Mallik. ADC Therapeutics' chances of upgrading its accelerated approval for diffuse large B-cell lymphoma therapy Zynlonta to a full approval have taken a ...

Just a few weeks after filing for bankruptcy protection, Sangamo Therapeutics has found buyers for some of its key assets, including a Fabry disease therapy and its genomic medicine platforms. PTC ...

In a first for the consumer health wearables category, Google has introduced a feature on its Pixel Watch and Fitbit Air devices that it says can monitor insulin resistance using passive sensors, ...

Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...

US cost-effectiveness watchdog ICER has concluded that AstraZeneca's first-in-class aldosterone synthase inhibitor (ASI) Baxfendy for resistant hypertension does not offer value for money. In a ...

Across the pharmaceutical industry, innovation has always been driven by a fundamental commitment to developing therapies that meaningfully improve patients’ lives. It’s a commitment that carries ...

A therapy room used to deliver the one-off, therapist-assisted treatment. Psychedelic drug developer Definium Therapeutics has reported positive phase 3 results with its LSD-based therapy, DT120, in ...

Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's sales prospects. The US regulator has ...